Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06592924 · ClinicalTrials.gov registry record · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
A Phase 3 study of Prostate Cancer (Adenocarcinoma), sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 830
- Enrollment target
- 20
- Study locations
NCT06592924: Recruiting Phase 3 study of Prostate Cancer (Adenocarcinoma), sponsored by Canadian Cancer Trials Group.
NCT06592924 is a Phase 3 study of Prostate Cancer (Adenocarcinoma) that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 830 participants, above the 66-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (1158% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06592924, a Phase 3 study of Prostate Cancer (Adenocarcinoma), is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 830 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Apalutamide
- DRUG Enzalutamide
- DRUG Abiraterone
- DRUG Darolutamide (BAY 1841788)
Study Locations (20)
California
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- Mercy Cancer Center - Carmichael - Carmichael
- Mercy San Juan Medical Center - Carmichael
- City of Hope Comprehensive Cancer Center - Duarte
- Mercy Cancer Center - Elk Grove - Elk Grove
- City of Hope at Irvine Lennar - Irvine
- City of Hope Antelope Valley - Lancaster
- City of Hope at Long Beach Elm - Long Beach
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Mercy Cancer Center - Merced
- Providence Queen of The Valley - Napa
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Arizona
- Cancer Center at Saint Joseph's - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 830 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2031-04-15 |
| Phase | Phase 3 |
What NCT06592924 shows while recruiting
NCT06592924 is an interventional study that assigns participants to a tested intervention. The registered 830 participants enrollment target is mid-sized for trials with a published cap, above the 66-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (1158% higher).
The record links to 1 condition, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT06592924 names 20 study sites across 3 states, led by California, Alaska, Arizona.
Frequently Asked Questions
What is clinical trial NCT06592924 about?
NCT06592924 is a clinical study titled "Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response". This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The us...
What is the current status of trial NCT06592924?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 830 participants. The study started on 2025-05-28. Estimated completion is 2031-04-15.
What conditions does trial NCT06592924 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma).
What interventions are being tested in trial NCT06592924?
The interventions under investigation include: Docetaxel (DRUG), Apalutamide (DRUG), Enzalutamide (DRUG), Abiraterone (DRUG), Darolutamide (BAY 1841788) (DRUG).
Who is sponsoring clinical trial NCT06592924?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06592924 being conducted?
This trial has 20 study locations across Alaska, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06592924's enrollment target sits among peer trials
830 1st of 13 higher than 13 of 13 other Prostate Cancer (Adenocarcinoma) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer (Adenocarcinoma) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
-
PSMA PET for Surveillance After Focal Therapy
RECRUITING · NA
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
RECRUITING
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06868277 · 830 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- NCT06910553 · 832 participants
IBD Pregnancy Registry
- NCT07089706 · 832 participants · Phase 4
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI